241 related articles for article (PubMed ID: 9346879)
1. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
[TBL] [Abstract][Full Text] [Related]
2. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta.
Pal S; Claffey KP; Cohen HT; Mukhopadhyay D
J Biol Chem; 1998 Oct; 273(41):26277-80. PubMed ID: 9756852
[TBL] [Abstract][Full Text] [Related]
3. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
[TBL] [Abstract][Full Text] [Related]
5. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
9. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Brieger J; Weidt EJ; Schirmacher P; Störkel S; Huber C; Decker HJ
J Mol Med (Berl); 1999 Jun; 77(6):505-10. PubMed ID: 10475065
[TBL] [Abstract][Full Text] [Related]
10. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
11. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Gnarra JR; Zhou S; Merrill MJ; Wagner JR; Krumm A; Papavassiliou E; Oldfield EH; Klausner RD; Linehan WM
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10589-94. PubMed ID: 8855222
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos O; Levy AP; Jiang C; Kaelin WG; Goldberg MA
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10595-9. PubMed ID: 8855223
[TBL] [Abstract][Full Text] [Related]
15. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
[TBL] [Abstract][Full Text] [Related]
16. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
17. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
18. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
de Paulsen N; Brychzy A; Fournier MC; Klausner RD; Gnarra JR; Pause A; Lee S
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1387-92. PubMed ID: 11171960
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Marti HH; Plate KH
Blood; 1998 Nov; 92(9):3388-93. PubMed ID: 9787178
[TBL] [Abstract][Full Text] [Related]
20. Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma.
Datta K; Mondal S; Sinha S; Li J; Wang E; Knebelmann B; Karumanchi SA; Mukhopadhyay D
Oncogene; 2005 Nov; 24(53):7850-8. PubMed ID: 16170373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]